You are here

  • Home
  • Archive
  • Volume 29, Issue 1
  • Bet 2: Doxapram resurrected? Weak evidence of efficacy suggests a potential use in patients ineligible for non-invasive ventilation

Article Text

Article menu
Download PDFPDF
Best Evidence Topic reports
Bet 2: Doxapram resurrected? Weak evidence of efficacy suggests a potential use in patients ineligible for non-invasive ventilation

https://doi.org/10.1136/emermed-2011-200981

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Report by: John J MacDonald

    Search checked by: Richard Body

    Institution: Stockport NHS Foundation Trust, Stockport, UK

    Clinical scenario

    A 73-year-old male with known chronic obstructive pulmonary disease (COPD) presents to the emergency department with dyspnoea. He is diagnosed with an acute exacerbation of COPD. Despite optimal medical management he fails to improve, his arterial blood gases demonstrate type II respiratory failure with worsening respiratory acidosis. He is offered a trial of non-invasive ventilation but refuses as. A decision is taken that invasive ventilation is not in the best interests of the patient. You wonder if the respiratory stimulant doxapram may improve the patient's respiratory failure.

    Three-part question

    In (patients with an acute exacerbation of COPD who are unwilling or unable to have ventilatory …

    View Full Text

    Footnotes

    • Linked articles 200980, 200982, 200983.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles